- Journal club critique
- Open Access
New strategies to manage complicated pleural effusions
© BioMed Central Ltd 2012
- Published: 22 May 2012
Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee YC, Hedley EL, Crosthwaite N, Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ: N Engl J Me d 2011, 365: 518-26. PMID: 21830966, available on www.pubmed. gov
More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is the key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial therapy (Multicenter Intrapleural Sepsis Trial [MIST1]).
Objective: To evaluate the efficacy and safety of intrapleural DNase alone, alteplase alone, or the combination of both, to improve pleural drainage.
Design: Multicenter, double-blind, double-dummy, 2 × 2 factorial randomized trial.
Setting: Eleven centers in the United Kingdom (UK).
Subjects: Adult patients (mean age 59 years, 72% men), who had clinical evidence of infection, and pleural fluid that had macroscopic purulence, a positive culture or Gram stain for bacteria, or a pH < 7.2.
Intervention: Patients were assigned to 1 of the 4 study interventions for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo.
Outcomes: The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events.
The mean (± SD) change in pleural opacity was greater in the t-PA-DNase group than in the placebo group (-29.5 ± 23.3% vs. -17.2 ± 19.6%; difference, -7.9%; 95% confidence interval [CI], -13.4 to -2.4; P = 0.005). The change observed with t-PA alone and with DNase alone (-17.2 ± 24.3 and -14.7 ± 16.4%, respectively) was not significantly different from that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P = 0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P = 0.006). Hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups.
Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of hospital stay. Treatment with DNase alone or t-PA alone was ineffective.
Rahman and colleagues should be commended for demonstrating that dual intrapleural therapy with t-PA and DNase in patients with pleural infection improved changes in opacity on chest x-ray and reduced need for surgical intervention and hospital stay. Although larger trials are needed to replicate these results, dual intrapleural therapy may be a useful option, especially for patients who are high-risk for surgery.
- Light RW, Girard WM, Jenkinson SG, George RB: Parapneumonic effusions. Am J Med 1980, 69: 507-512. 10.1016/0002-9343(80)90460-XView ArticlePubMedGoogle Scholar
- Ahmed AE, Yacoub TE: Empyema thoracis. Clin Med Insights Circ Respir Pulm Med 2010, 4: 1-8.PubMed CentralPubMedGoogle Scholar
- Davies CW, Kearney SE, Gleeson FV, Davies RJ: Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999, 160: 1682-1687.View ArticlePubMedGoogle Scholar
- Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR: Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg 2007, 133: 346-351. 10.1016/j.jtcvs.2006.09.038View ArticlePubMedGoogle Scholar
- Kroegel C, Antony VB: Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997, 10: 2411-2418. 10.1183/09031936.97.10102411View ArticlePubMedGoogle Scholar
- Davies CW, Gleeson FV, Davies RJ: BTS guidelines for the management of pleural infection. Thorax 2003,58(Suppl 2):ii18-28.PubMed CentralView ArticlePubMedGoogle Scholar
- Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A: Early use of intrapleural fibrinolytics in the management of postpneumonic empyema:a prospective study. Eur J Cardiothorac Surg 2005, 28: 599-603. 10.1016/j.ejcts.2005.07.005View ArticlePubMedGoogle Scholar
- Simpson G, Roomes D, Heron M: Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000, 117: 1728-1733. 10.1378/chest.117.6.1728View ArticlePubMedGoogle Scholar
- Tokuda Y, Matsushima D, Stein GH, Miyagi S: Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006, 129: 783-790. 10.1378/chest.129.3.783View ArticlePubMedGoogle Scholar
- Heffner JE: Multicenter trials of treatment for empyema -- after all these years. N Engl J Med 2005, 352: 926-8. 10.1056/NEJMe048352View ArticlePubMedGoogle Scholar